Lung cancer is a major cause of death despite diagnostic and therapeutic improvements. The overall 5-year survival rate is less than 10%. However, the prognosis can be modulated by characteristics related to the patient or to the tumour. Some independent prognostic factors for survival have already been identified. They include, for small-cell lung cancer (SCLC): disease extent and performance status (PS) ([Paesmans *et al*, 2000](#bib42){ref-type="other"}); for non-small cell lung cancer (NSCLC): PS, stage and, with lower impact, age, sex and weight loss ([Paesmans *et al*, 1995](#bib43){ref-type="other"}; [Strauss, 1997](#bib63){ref-type="other"}).

With the recent progresses in molecular biology, the research on prognostic factors could be extended to proteins and genes involved in cancer development. The biological factors implicated in carcinogenesis should also be considered as potential survival prognostic factors. Some of them, like angiogenesis and factors reflecting proliferative state, have already been identified in patients with lung cancer ([Kanters *et al*, 1995](#bib21){ref-type="other"}). In order to clarify the prognostic impact of other biological factors in lung cancer, our group has performed systematic reviews of the literature with meta-analyses. It allowed us to show that VEGF ([Delmotte *et al*, 2002](#bib6){ref-type="other"}), microvessel density ([Meert *et al*, 2002b](#bib34){ref-type="other"}), c-erbB-2 ([Meert *et al*, 2003](#bib33){ref-type="other"}) and p53 ([Steels *et al*, 2001](#bib62){ref-type="other"}) have statistically significant worse impact on survival, while Bcl-2 ([Martin *et al*, 2003](#bib31){ref-type="other"}) has a favourable survival impact.

Oncogenes (RAS, Raf, Myc, Src, Abl/Bcr, c-erbB-2, ...) are derived from normal genes (the proto-oncogene) coding for proteins, which play key roles in physiological cellular processes such as regulations of gene expression or growth signal transduction. Particularly, RAS oncogene is involved in lung cancer development. Three human RAS genes ([Rodenhuis and Slebos, 1990](#bib49){ref-type="other"}) have been identified: the HRAS gene (homologous to the oncogene of the Harvey rat sarcoma virus), the KRAS2 gene (homologous to the oncogene of the Kirsten rat sarcoma virus) and the NRAS gene (first isolated from a human neuroblastoma). These genes code for four highly homologous 21 kDa proteins called p21, with a common effector domain within the N-terminal region. To be biologically active, RAS proteins must be localised to the inner face of the plasma membrane, where they can effectively interact with their upstream activators and downstream targets. The RAS gene proteins can exist in two states: an active state, in which GTP is bound to the molecule and an inactive state, in which the GTP has been hydrolysed to GDP. In physiologic conditions, the active isoform initiates cell proliferation through the RAS-dependent kinase cascade. The RAS proteins possess intrinsic GTPase activity, which normally leads to their inactivation and the control of cell growth. In tumours, a point mutation resulting in loss of the intrinsic GTPase activity appears to be associated with transforming activity of the protein, which does not stop anymore to send the signal stimulating cell proliferation. KRAS2 mutations are particularly common in pancreatic cancers, colorectal malignancies and lung cancer ([Rodenhuis, 1992](#bib47){ref-type="other"}; [Minamoto *et al*, 2000](#bib35){ref-type="other"}).

RAS mutations are detected in 15--20% of NSCLC and, particularly, 30--50% of adenocarcinomas (ADC) ([Rodenhuis *et al*, 1988](#bib50){ref-type="other"}). In lung cancer, 90% of the mutations are located in the RAS2 gene and both NRAS mutations and HRAS mutations have occasionally been documented ([Rodenhuis and Slebos, 1990](#bib49){ref-type="other"}). In total, 80% of KRAS2 mutations occur in codon 12. Other mutations are located in codons 13 and 61. The predominant mutation is a G--T transversion (70% of tumours) ([Rodenhuis and Slebos, 1990](#bib49){ref-type="other"}).

The literature remains controversed on the prognostic value of RAS for survival in patients with lung cancer. In order to clarify this question, we have performed a systematic review of the literature with methodological assessment and meta-analysis.

MATERIALS AND METHODS
=====================

Publications selection
----------------------

To be eligible for the systematic review, a study had to fulfil the following criteria: to deal only with lung cancer (any stage or histology), to assess the correlation between RAS mutation or p21 expression and survival, to analyse RAS-p21 in the primary tumour (not in metastatic tissue or tissue adjacent to the tumour) and/or antibodies against p21 in the serum, to have been published as a full paper in the English or French language. Abstracts were excluded because they do not provide sufficient data to evaluate the methodological quality of the trial and/or to perform meta-analysis.

Studies were identified by an electronic search on Medline databank and using the following keywords: 'lung cancer\', 'lung carcinoma\', 'lung neoplasms\', 'lung tumour\', 'lung tumours\', 'lung tumour\', 'lung tumours\', 'lung adenocarcinoma\', 'lung squamous\', 'NSCLC\', 'non-small cell lung cancer\', 'non small cell lung cancer\', 'non-small cell lung carcinoma\', 'non small cell lung carcinoma\', 'SCLC\', 'small cell lung cancer\', 'small cell lung carcinoma\', 'ras\', 'K-ras\', 'Ki-ras\', 'n-ras\', 'c-ras\', 'l-ras\', 'h-ras\', 'p21\'. The search ended on July 2003. The bibliographies reported in all the identified studies were used to complete this search. When the authors reported results obviously obtained on the same patients population in several publications, only the most recent or the most complete study was included in the analysis, in order to avoid overlapping between cohorts.

Methodological assessment
-------------------------

To assess the quality of the methodology, each study was read independently by 12 investigators, including nine physicians and three scientists. The participation of many readers was a guarantee for the correct interpretation of the articles. The methodological evaluation was scored according to the European Lung Cancer Working Party (ELCWP) scale. The scoring system used has already been described in one of our prior systematic reviews ([Steels *et al*, 2001](#bib62){ref-type="other"}). Each item was assessed using an ordinal scale (possible values: 2, 1, 0). A consensus was reached in regular meetings where at least two-thirds of the investigators needed to be present. As the assessed items were objective ones, a consensus was always obtained.

The overall score evaluated several dimensions of the methodology, grouped into four main categories: the scientific design, the description of laboratory methods used to identify the presence of RAS mutation or p21 expression, the generalisability of the results and the analysis of the study data. Each category had a maximum score of 10 points, with a maximal theoretical score of 40 points. When an item was not applicable to a study, its value was not taken into account in the total of the concerned category. The final scores were expressed as percentages, ranging from 0 to 100%, higher values reflecting better methodological quality. Studies included in the systematic review were called 'eligible\', those providing sufficient data for the meta-analysis 'evaluable\'. To be eligible, studies had to provide univariate analysis.

Statistical methods
-------------------

A study was considered as significant if the *P*-value for the statistical test comparing survival distributions between the groups with and without RAS-p21 alteration was \<0.05. A study was called 'positive\' when a mutation/expression in RAS-p21 proto-oncogene was identified as a significant favourable prognostic factor for survival. The study was called 'negative\' if the same characteristic was associated with a significant detrimental impact on survival. Finally, a study was called 'not significant\' if no statistically significant difference between the two groups was detected and 'not conclusive\' if any conclusion about significance of survival results could be derived from the article.

The association between two continuous variables was measured by the Spearman rank correlation coefficient. Nonparametric tests were used to compare the distribution of the quality scores according to the value of a discrete variable (Mann--Whitney tests for dichotomic variables or Kruskal--Wallis tests for multiple classes variables).

For the quantitative aggregation of the survival results, we measured the impact of RAS mutation and/or p21 expression on survival by hazard ratio (HR) between the two survival distributions. For each trial, this HR was estimated by a method depending on the data provided in the publication. The most accurate method consisted of calculating the estimated HR and its standard error (s.e.) from the reported results or to calculate them directly using two of the following parameters: the O-E statistic (difference between numbers of observed and expected events), the confidence interval (CI) for the HR, the logrank statistic or its *P*-value. If these were not available, the total number of events, the number of patients at risk in each group and the logrank statistic or its *P*-value were used to allow for an approximation of the HR estimate. Finally, if the only exploitable data were in form of graphical representations of the survival distributions, survival rates at some specified times were extracted in order to reconstruct the HR estimate and its variance, with the assumption that the rate of patients censored was constant during the study follow-up ([Parmar *et al*, 1998](#bib44){ref-type="other"}). If this last method was used, three independent persons read the curves to reduce inaccuracy in the extracted survival rates. The individual HR estimates were combined into an overall HR using Peto\'s method ([Yusuf *et al*, 1985](#bib71){ref-type="other"}), which consisted of using a fixed effect model assuming homogeneity of the individual true HRs. This assumption was tested by performing *χ*^2^ tests for heterogeneity. If the assumption of homogeneity had to be rejected, we used a random-effect model as a second analysis. By convention, an observed HR\<1 implied a better survival for the group with mutated RAS or p21 expression. This impact of RAS on survival was considered as statistically significant if the 95% confidence interval for the overall HR did not overlap 1.

When data about global survival of the entire patients population were available, survival was analysed globally. If authors only reported the results separately for different subgroups, those results corresponded to different cohorts of patients and were treated separately in the meta-analysis.

RESULTS
=======

Study selection and characteristics
-----------------------------------

In total, 53 publications, published between 1990 and 2003, were found eligible for the systematic review ([Rodenhuis *et al*, 1988](#bib50){ref-type="other"}, [1997](#bib48){ref-type="other"}; [Slebos *et al*, 1990](#bib61){ref-type="other"}; [Mitsudomi *et al*, 1991](#bib36){ref-type="other"}; [Miyamoto *et al*, 1991](#bib38){ref-type="other"}; [Harada *et al*, 1992](#bib16){ref-type="other"}; [Sugio *et al*, 1992](#bib64){ref-type="other"}; [Rosell *et al*, 1993](#bib51){ref-type="other"}, [1995b](#bib53){ref-type="other"}, [1996](#bib54){ref-type="other"}, [1997](#bib55){ref-type="other"}; [Volm *et al*, 1993](#bib67){ref-type="other"}, [2002](#bib68){ref-type="other"}; [Westra *et al*, 1993](#bib70){ref-type="other"}; [Kern *et al*, 1994](#bib25){ref-type="other"}; [Li *et al*, 1994](#bib30){ref-type="other"}; [Silini *et al*, 1994](#bib60){ref-type="other"}; [Fujino *et al*, 1995](#bib11){ref-type="other"}; [Kashii *et al*, 1995](#bib22){ref-type="other"}; [Keohavong *et al*, 1996](#bib23){ref-type="other"}, [1997](#bib24){ref-type="other"}; [Cho *et al*, 1997](#bib4){ref-type="other"}; [Dosaka-Akita *et al*, 1997](#bib8){ref-type="other"}; [Fukuyama *et al*, 1997](#bib12){ref-type="other"}; [Komiya *et al*, 1997](#bib27){ref-type="other"}; [Pifarré *et al*, 1997](#bib45){ref-type="other"}; [Siegfried *et al*, 1997](#bib59){ref-type="other"}; [Visscher *et al*, 1997](#bib66){ref-type="other"}; [De Gregorio *et al*, 1998](#bib5){ref-type="other"}; [Greatens *et al*, 1998](#bib14){ref-type="other"}; [Huang *et al*, 1998](#bib18){ref-type="other"}; [Kim *et al*, 1998](#bib26){ref-type="other"}; [Kwiatkowski *et al*, 1998](#bib29){ref-type="other"}; [Nemunaitis *et al*, 1998](#bib41){ref-type="other"}; [Wang *et al*, 1998](#bib69){ref-type="other"}; [Dingemans *et al*, 1999](#bib7){ref-type="other"}; [Fu *et al*, 1999](#bib10){ref-type="other"}; [Graziano *et al*, 1999](#bib13){ref-type="other"}; [Miyake *et al*, 1999](#bib37){ref-type="other"}; [Nelson *et al*, 1999](#bib40){ref-type="other"}; [Hommura *et al*, 2000](#bib17){ref-type="other"}; [Konishi *et al*, 2000](#bib28){ref-type="other"}; [Moldvay *et al*, 2000](#bib39){ref-type="other"}; [Schneider *et al*, 2000](#bib57){ref-type="other"}; [Andjelic *et al*, 2001](#bib2){ref-type="other"}; [Kang *et al*, 2001](#bib20){ref-type="other"}; [Schiller *et al*, 2001](#bib56){ref-type="other"}; [Ahrendt *et al*, 2002](#bib1){ref-type="other"}; [Broermann *et al*, 2002](#bib3){ref-type="other"}; [Shoji *et al*, 2002](#bib58){ref-type="other"}; [Tomizawa *et al*, 2002](#bib65){ref-type="other"}; [Grossi *et al*, 2003](#bib15){ref-type="other"}; [Ramirez *et al*, 2003](#bib46){ref-type="other"}). In all, 10 of these articles were excluded because an identical patient cohort had been used in other selected publications ([Rodenhuis *et al*, 1988](#bib50){ref-type="other"}; [Miyamoto *et al*, 1991](#bib38){ref-type="other"}; [Fujino *et al*, 1995](#bib11){ref-type="other"}; [Rosell *et al*, 1995a](#bib52){ref-type="other"}, [1995b](#bib53){ref-type="other"}, [1996](#bib54){ref-type="other"}; [Dosaka *et al*, 1997](#bib8){ref-type="other"}; [Keohavong *et al*, 1997](#bib24){ref-type="other"}; [Hommura *et al*, 2000](#bib17){ref-type="other"}; [Konishi *et al*, 2000](#bib28){ref-type="other"}; [Volm *et al*, 2002](#bib68){ref-type="other"}). One of the 43 remaining studies ([Volm *et al*, 1993](#bib67){ref-type="other"}) assessed separately by immunohistochemistry (IHC) KRAS2, NRAS and HRAS p21. All the other papers concerned KRAS2 only. Therefore, for the meta-analysis, we took into account only the characteristics and the data concerning KRAS2 p21 expression.

The total number of included patients was 5216, ranging from 21 to 355 patients per study (median: 103). The main characteristics of the 43 publications eligible for the systematic review are reported in [Table 1](#tbl1){ref-type="table"}. In total, 27 were dealing with NSCLC, 11 with adenocarcinoma only, three with any histological type, one with SCLC and one with both ADC and large cell carcinoma. A total of 22 studies concerned only nonmetastatic disease, one only stage IV disease and 19 all stages (I--IV). One study did not mention the stage of the tumours. In 15 publications, patients were treated by surgery alone. Surgery was associated with an adjuvant therapy (radiotherapy and/or chemotherapy) in 26. In one study, SCLC patients were treated with a combination of radiotherapy and chemotherapy ([Dingemans *et al*, 1999](#bib7){ref-type="other"}). In the last paper, treatment was not described [De Gregorio *et al*, 1998](#bib5){ref-type="other"}).

Nine studies evaluated the accumulation of p21 protein by IHC. The other 34 identified RAS mutation by molecular biology, using different polymerase chain reaction (PCR) methodologies, mainly, single-strand conformation polymorphism (SSCP) (*n*=10) and restriction fragment length polymorphism (RFLP) (*n*=8).

Among the 43 studies eligible for the systematic review, 14 were inevaluable for the meta-analysis due to insufficient data reported in the article. The reasons for noninclusion of a study into the meta-analysis were the lack of available survival results to calculate HR in 13 ([Volm *et al*, 1993](#bib67){ref-type="other"}; [Westra *et al*, 1993](#bib70){ref-type="other"}; [Li *et al*, 1994](#bib30){ref-type="other"}; [Kashii *et al*, 1995](#bib22){ref-type="other"}; [Pifarré *et al*, 1997](#bib45){ref-type="other"}; [Visscher *et al*, 1997](#bib66){ref-type="other"}; [De Gregorio *et al*, 1998](#bib5){ref-type="other"}; [Greatens *et al*, 1998](#bib14){ref-type="other"}; [Fu *et al*, 1999](#bib10){ref-type="other"}; [Miyake *et al*, 1999](#bib37){ref-type="other"}; [Schneider *et al*, 2000](#bib57){ref-type="other"}; [Andjelic *et al*, 2001](#bib2){ref-type="other"}; [Broermann *et al*, 2002](#bib3){ref-type="other"}) and the lack of repartition of tumours according to RAS mutation/expression in 1 ([Ahrendt *et al*, 2002](#bib1){ref-type="other"}).

Study results report
--------------------

Nine of the 43 studies (20.9%) identified proto-oncogene RAS mutations or p21 overexpression as a pejorative prognostic factor for survival (with seven evaluable for the meta-analysis), 31 (72.1%) concluded that RAS was not a prognostic factor for survival (21 evaluable), one (2.3%) reported a better prognosis for RAS positivity (evaluable) and two (4.7%) were nonconclusive (both nonevaluable).

Overall, the rates of RAS mutations detected by PCR and p21 protein overexpression were, respectively, 18.4% (number of evaluable tumours (*n*)=3779) and 44.6% (*n*=1548) in NSCLC, 7.1% (*n*=141) and 32.3% (*n*=223) in squamous cell carcinomas (SQCC) and 23.1% (*n*=1847) and 34.7% (*n*=222) in ADC. The rates of positive tumours by molecular biology or IHC were, respectively, 21.8% (*n*=1015) and 54.8% (*n*=135) in stage I NSCLC, 16.0% (*n*=399) and 53.5% (*n*=71) in NSCLC patients with stages I and II, 16.2% (*n*=1263) and 38.5% (*n*=929) in those with stages I--III.

Quality assessment
------------------

The overall quality score ranged from 31.04 to 78.15% with a median of 52.2% ([Table 2A](#tbl2){ref-type="table"}). The design subscore had the lowest value, with a median of 40%.

No statistically significant quality difference was shown between significant and nonsignificant studies neither for the global score (median: 51.50 *vs* 53.83%, *P*=0.90), neither for the four subgroups scores. There was also no statistically significant difference between evaluable and nonevaluable studies for meta-analysis in terms of global scores (55.23 *vs* 44.31%, *P*=0.10), but the evaluable ones had a better score concerning the report of the analysis results: 62.5% in comparison to 31.3% for the nonevaluable trials (*P*=0.001). There was a significant correlation between the global score and the number of patients included (Spearman correlation coefficient *r*=0.50, *P*=0.0006), studies including a higher number of patients showing a better global score. The generalisability of the results was significantly better in the recent publications (*r*=0.42, *P*=0.004). There was also a statistically significant difference between studies assessing RAS-p21 status by IHC (*n*=9) or by molecular biology (*n*=34), with global scores of 58.51 and 49.93%, respectively (*P*=0.029) and scores assessing the description of the laboratory methodology of 64.3 *vs* 46%, those based on IHC being better described than those on molecular biology (*P*=0.002).

[Table 2B](#tbl2){ref-type="table"} reports the analysis of the scores for the 29 studies evaluable for meta-analysis. Their overall quality score ranged between 34.25 and 78.15%, with a median of 55.24%. The design subscore was also the worst reported. Like previously observed among eligible publications, there was no statistically significant difference between significant and nonsignificant studies evaluable for the meta-analysis according to the global score (median of 53.04 *vs* 53.42%, *P*=0.92). There was also a significant correlation between global score and the number of patients included in the study (Spearman correlation coefficient *r*=0.53, *P*=0.006) and those assessing RAS positivity by IHC obtained a better quality scores for the laboratory method subgroup (57.1 *vs* 50% for molecular biology, *P*=0.04), but not for the global score.

Meta-analysis
-------------

The absence of significant methodological quality difference between significant and nonsignificant studies allowed us to perform a quantitative aggregation of the survival results. The meta-analysis was performed on 28 studies (3620 patients) dealing with NSCLC.

The individual HR of the 28 aggregable studies were calculated by one of the three methods reported in the Materials and Methods section according to the available data. Only six studies reported the data needed to directly calculate the estimated HR (HRs and 95% confidence intervals). In 10 trials, HR was approximated by the total number of events and the logrank statistic. For the 12 remaining studies, HR had to be extrapolated from the graphical representation of the survival distributions.

The NSCLC overall meta-analysis included the 28 aggregable studies with a total number of 3620 patients. Two trials ([Fukuyama *et al*, 1997](#bib12){ref-type="other"}; [Moldvay *et al*, 2000](#bib39){ref-type="other"}) gave only subgroup survival analysis and their data were analysed separately like reported by authors, increasing the number of individual cohorts aggregated to 30. The aggregation of the survival data is described in [Table 3](#tbl3){ref-type="table"}. Overall RAS mutation or p21 expression was associated with a worse survival (HR (fixed effect model) 1.30; 95% confidence intervals (CI) 1.20--1.49). The test of heterogeneity was significant (*P*=0.01). Nevertheless, we calculated the HR by a random effect model that showed also a statistically significant impact on survival with an HR of 1.35 (95% CI: 1.16--1.56).

In the subgroup analysis ([Table 3](#tbl3){ref-type="table"}) according to histology, RAS/p21 was not a statistically significant prognostic factor for survival in SQCC (H: 1.49, CI 95%: 0.88--2.52), but well in ADC, with heterogeneity between the trials (heterogeneity test: *P*=0.02) and a random effect HR of 1.59 (CI 95%: 1.26--2.02). The meta-analysis of studies into three subgroups according to stages (stage I, stage I--III and stage I--IV) did not show any statistically significant impact of RAS on survival. For the last subgroup (stage I--IV) there were 11 studies with a large heterogeneity (*P*\<0.001) and the random effect HR was borderline (1.41, 95% CI: 0.99--1.99).

Furthermore, we aggregated the studies separately according to the method used to detect RAS/p21 alteration ([Table 3](#tbl3){ref-type="table"}). The studies were first divided into two main groups according to the laboratory method: IHC ([Figure 1](#fig1){ref-type="fig"}) or molecular biology ([Figure 2](#fig2){ref-type="fig"}), including the different techniques of PCR. The fixed effect HR were respectively 1.08 (95% CI: 0.86--1.34) and 1.39 (95% CI: 1.22--1.58) for IHC and molecular biology. For PCR, there was a statistically significant heterogeneity (*P*=0.03) and the random effect HR was 1.40 (95% CI: 1.18--1.65). Among the studies with PCR based revelation technique, two methods, PCR-RFLP and PCR-SSCP, were used in respectively six and three studies. Fixed effect HR of 1.7 (95% CI: 1.31--2.19) and 1.32 (95% CI: 0.72--1.47) were obtained, respectively, the first one only being statistically significant.

Finally, we decided to perform an analysis in histological subgroups separately according to the method of detection. There were only four studies dealing with SQCC and it was a nonsense to make more reduced subgroups analysis. We were able to analyse studies including ADC separating those using IHC from those applying PCR. Four studies were using IHC only. The HR (random-effects model, p heterogeneity test=0.01) was 1.48 (95% CI 0.76--2.87). The HR (fixed-effects model, p heterogeneity test=0.1) for 11 studies assessing RAS mutation by PCR in ADC was 1.50 (95% CI 1.26--1.80) ([Figure 3](#fig3){ref-type="fig"}).

DISCUSSION
==========

The present systematic review of the literature with meta-analysis shows that RAS gene alteration and/or protein p21 overexpression is a poor prognostic factor for survival of patients with NSCLC in univariate analysis. In subgroup analysis, the negative prognostic value of RAS alterations is observed in ADC but not for SQCC and when PCR is used as revelation method but not when IHC is used.

Our data help so to clarify the message of individual studies, arguing with the hypothesis that RAS is a prognostic factor for lung cancer. This still needs to be confirmed in prospective trials with appropriate multivariate analysis taking into account other clinical or biological prognostic factors. Another meta-analysis based on a review of the literature on the role of KRAS2 as prognostic factor in lung cancer was previously published ([Huncharek *et al*, 1999](#bib19){ref-type="other"}). Only eight trials ([Slebos *et al*, 1990](#bib61){ref-type="other"}; [Kern *et al*, 1994](#bib25){ref-type="other"}; [Silini *et al*, 1994](#bib60){ref-type="other"}; [Rosell *et al*, 1995a](#bib52){ref-type="other"}; [Cho *et al*, 1997](#bib4){ref-type="other"}; [Fukuyama *et al*, 1997](#bib12){ref-type="other"}; [Rodenhuis *et al*, 1997](#bib48){ref-type="other"}; [Siegfried *et al*, 1997](#bib59){ref-type="other"}) were included because the selection criteria of the studies were different from ours: the search for studies ended in 1997, only trials documenting KRAS2 mutation by PCR (and not those with IHC) were included, other histologies than NSCLC were excluded, 2-year survival rates had to be described. The authors observed that KRAS2 mutations detected by different PCR variants were poor prognostic factor for NSCLC. These results support the validity of ours. No subgroup analyses according to stage or histology (ADC *vs* SQCC) were performed, not allowing us to compare with our results.

RAS gene mutations are involved in oncogenesis of a variety of human tumours ([Rodenhuis and Slebos, 1990](#bib49){ref-type="other"}). In lung cancer, [Fisher *et al* (2001)](#bib9){ref-type="other"} has demonstrated that RAS mutation is necessary for induction and maintenance of lung cancer. The same author showed that lung tumours arising in the absence of tumour suppressor gene remain dependent on mutant KRAS2 for maintenance of tumour growth and that apoptosis after KRAS2 downregulation does not require p53 or Ink4A/Arf. Those points suggest that RAS plays a key role in lung carcinogenesis. Moreover, the present demonstration of its prognostic role in lung suggests that the detection of RAS alteration would also allow us to stratify patients with higher risk. It could also determine patients with a better chance to respond to specific treatment targeting RAS.

To avoid bias due to a more detailed reporting of significant trials, we decided to perform a methodological assessment of the publications prior to quantitative aggregation. We have used a methodology similar to previous systematic reviews reported by our group about biological prognostic factors in lung cancer ([Steels *et al*, 2001](#bib62){ref-type="other"}; [Delmotte *et al*, 2002](#bib6){ref-type="other"}; [Meert *et al*, 2002a](#bib32){ref-type="other"}, [2002b](#bib34){ref-type="other"}; [Martin *et al*, 2003](#bib31){ref-type="other"}; [Meert *et al*, 2003](#bib33){ref-type="other"}). The absence of a statistically significant difference in quality score between the significant and the nonsignificant publications allowed us to perform a quantitative aggregation (meta-analysis) of the results of the individual trials. However, this approach does not prevent all potential biases. Biases including publication bias, choice of language, selection of fully published studies only, method of extrapolation of HR, validity of a meta-analyses based on systematic review of the literature as compared with those based on individual data were already discussed in our previous papers ([Steels *et al*, 2001](#bib62){ref-type="other"}; [Delmotte *et al*, 2002](#bib6){ref-type="other"}; [Meert *et al*, 2002a](#bib32){ref-type="other"}, [2002b](#bib34){ref-type="other"}; [Martin *et al*, 2003](#bib31){ref-type="other"}; [Meert *et al*, 2003](#bib33){ref-type="other"}).

Some eligible trials had to be excluded from the meta-analysis because they did not provide sufficient data on survival. Among the 14 excluded studies, 12 were nonsignificant (86%) while a lower proportion of the studies evaluable for the meta-analysis were nonsignificant (70%). It is known that negative studies are less frequently published or, if they are, with less detailed results, making them less assessable. However, the methodological quality of trials, according to the global score, was not significantly different between evaluable and nonevaluable studies for the quantitative aggregation of individual survival results.

Some results need comments: we only demonstrated significant impact of RAS alterations in ADC and not in SQCC. This observation suggests that the biological signalling pathways implicated in carcinogenesis are different for ADC and for SQCC. Those information should interpreted carefully because RAS mutations are more frequently observed in ADC as compared with SQCC (23.12 *vs* 7.09%) Moreover, authors more often assessed ADC rather than SQCC (1436 *vs* 280 patients in the meta-analysis). For example, Nelson\'s trial ([Nelson *et al*, 1999](#bib40){ref-type="other"}), firstly based on all histological subtypes, did not detect any mutation in squamous cell carcinoma and thus did not report data on this histological subtype. Another example arises in Moldvay's study ([Moldvay *et al*, 2000](#bib39){ref-type="other"}): she assessed overexpression of p21 by IHC in all tumours but only evaluate RAS mutation by PCR in ADC and not in SQCC. There is a potential bias to evalue the impact of RAS in squamous cell carcinomas and this should be further investigated.

The diversity in the techniques used to identify alteration of RAS-p21 status can also be a potential source of bias. Firstly, IHC is not comparable among the nine studies. There were six different primary antibodies, different revelation protocols and different level of positivity (from 0 to 50% or only based on intensity). Secondly, there is not a good correlation between DNA mutation and protein conformation or level of protein expression and thus between molecular biology and IHC. Authors ([Nelson *et al*, 1999](#bib40){ref-type="other"}; [Moldvay *et al*, 2000](#bib39){ref-type="other"}) who studied RAS mutation and p21 expression on the same tumours did not find any correlation between the two abnormalities. Particularly, Nelson ([Nelson *et al*, 1999](#bib40){ref-type="other"}) did not observe significant impact of p21 expression in multivariate analysis (*P*=0.89), but well for RAS mutation (*P*=0.04). Moldvay ([Moldvay *et al*, 2000](#bib39){ref-type="other"}) only found three patients among 81 analysed with both RAS IHC staining and KRAS2 point mutation. It could bring some potential explanations to the difference between IHC and PCR in our meta-analysis. PCR seems to be a more accurate technique to assess RAS in lung tumours. It is interesting to observe that we previously had never showed differences between the two techniques for other markers like p53 ([Steels *et al*, 2001](#bib62){ref-type="other"}). This suggests the importance to determine the best method to assess each marker. There was also a difference between RFLP- and SSCP-PCR, only the first one showing statistically significant impact on survival of patient with lung cancer. There were only three trials with SSCP-PCR and the results reached to be significant. There is thus need to confirm or infirm those results prospectively with an adequately designed and powered trial. The PCR techniques used were thus different between the trials and between the specific KRAS2 codon analysed. Whatever, in the other meta-analysis ([Huncharek *et al*, 1999](#bib19){ref-type="other"}), pooling all trials with PCR with an heterogeneity detected according to different procedure and codon analysed, the results reached significance. For clinical application, the best method to assess KRAS2 still needs to be determined in further studies to provide reproductible results and standardised evaluation.

In conclusion, our systematic review suggests that RAS mutation or p21 expression is of poor prognostic significance for survival in patients with non-small-cell lung cancer. The results were based on an aggregation of data obtained by univariate analysis in retrospective trials. In order to become a useful prognostic factor at the level of individual patients and in the context of targeted therapy, these results need to be confirmed by an adequately designed prospective study and the exact value of p21 expression needs to be determined by an appropriate multivariate analysis taking into account the classical well-defined prognostic factors for lung cancer. Moreover, molecular biology arises as a more accurate technique to assess RAS alteration as compared with IHC. It is a priority to confirm those data in order to determine the adequate method to assess RAS, which would then further allow performing prospective studies with adequate design and, particularly, adapted laboratory methods.

![Meta-analysis of studies assessing RAS with IHC in NSCLC. Hazard ratio (HR) and 95% confidence interval (CI) of survival in studies evaluating RAS-p21 status in NSCLC. HR\>1 implies a survival disadvantage for the group with p21 expression. The square size is proportional to the number of patients included in the study. The center of the lozenge gives the combined HR of the meta-analysis and its extremities the 95% confidence interval. HR=1.08; CI 95% 0.86--1.34. Total number of patients: 989.](92-6602258f1){#fig1}

![Meta-analysis of studies assessing RAS mutation with PCR in NSCLC. Hazard ratio (HR) and 95% confidence interval (CI) of survival in studies evaluating RAS-p21 status in NSCLC. HR\>1 implies a survival disadvantage for the group with RAS mutation. The square size is proportional to the number of patients included in the study. The centre of the lozenge gives the combined HR of the meta-analysis and its extremities the 95% confidence interval. HR=1.40; CI 95% 1.18--1.65. Total number of patients: 2631.](92-6602258f2){#fig2}

![Meta-analysis of studies assessing RAS mutation by PCR in adenocarcinomas. Hazard ratio (HR) and 95% confidence interval (CI) of survival in studies evaluating RAS-p21 status in NSCLC. HR\>1 implies a survival disadvantage for the group with RAS mutation. The square size is proportional to the number of patients included in the study. The centre of the lozenge gives the combined HR of the meta-analysis and its extremities the 95% confidence interval. HR=1.50; CI 95% 1.26--1.80. Total number of patients: 1170.](92-6602258f3){#fig3}

###### 

Main characteristics and results of the eligible studies

  **First author**   **Year**   **Histology**   **Stage**   ***N* pts**   **Laboratory method**   **HR estimation**   **Survival results**
  ------------------ ---------- --------------- ----------- ------------- ----------------------- ------------------- ----------------------
  Ahrendt            2002       NSCLC           I--IIIA     60            PCR-seq                 No data             NC
  Andjelic           2001       NSCLC           IIIA        21            PCR-SSCP                No data             Negative
  Broermann          2002       NSCLC           III         28            PCR-RFLP                No data             NS
  Cho                1997       NSCLC           I--IIIB     58            PCR-SSCP                Survival curves     Negative
  De Gregorio        1998       ADC             I--IV       184           PCR                     No data             NS
  Dingemans          1999       SCLC            ANY         93            IHC                     Survival curves     NS
  Fu                 1999       NSCLC           I--IIIB     158           IHC                     No data             NS
  Fukuyama           1997       NSCLC           I--IV       159           PCR-RFLP                Survival curves     Negative
  Graziano           1999       NSCLC           I--II       213           PCR                     Log rank            NS
  Greatens           1998       NSCLC           I--IV       101           PCR-SSCP                No data             NS
  Grossi             2003       NSCLC           I--IIIA     249           PCR                     HR                  NS
  Harada             1992       NSCLC           I--IV       94            IHC                     Survival curves     Negative
  Huang              1998       NSCLC           I--IIIB     144           PCR-SSCP                Survival curves     Negative
  Kang               2001       NSCLC           I--IIIB     61            IHC                     HR                  NS
  Kashii             1995       ALL             I--IV       97            PCR-SSCP                No data             NS
  Keohavong          1996       NSCLC           I--IV       126           PCR-DGGE                Log rank            NS
  Kern               1994       ADC             I--IV       44            PCR-ASO                 HR                  NS
  Kim                1998       NSCLC           I--IV       238           IHC                     HR                  NS
  Komiya             1997       NSCLC           I--IIIA     137           IHC                     Survival curves     NS
  Kwiatkowski        1998       NSCLC           I           244           PCR-RFLP                Log rank            NS
  Li                 1994       ADC             I--?        41            PCR-dot blot            No data             NS
  Mitsudomi          1991       ALL             I--IV       66            PCR-RFLP                Log rank            NS
  Miyake             1999       NSCLC           I--IIIB     187           PCR-SSCP                No data             Negative
  Moldvay            2000       NSCLC           I--IV       227           IHC                     Log rank            NS
  Nelson             1999       NSCLC           I--IV       355           PCR-RFLP                Survival curves     Negative
  Nemunaitis         1998       ADC+LC          I--IV       103           PCR-RFLP                Survival curves     NS
  Pifarre            1997       NSCLC           I--IIIA     64            PCR-SSCP                No data             NC
  Ramirez            2003       NSCLC           I--IV       50            PCR                     Survival curves     NS
  Rodenhuis          1997       ADC             III--IV     62            EPCR                    Log rank            NS
  Rosell             1997       NSCLC           I           35            PCR-SSCP                Log rank            NS
  Rosell             1993       NSCLC           I--IIIA     66            PCR-RFLP                Log rank            Negative
  Schiller           2001       NSCLC           II--IIIA    184           PCR-RFLP                HR                  NS
  Schneider          2000       NSCLC           I--IIIA     103           PCR-SSCP                No data             NS
  Shoji              2002       NSCLC           I--IIIA     233           IHC                     Survival curves     Positive
  Siegfried          1997       ADC             I--IV       181           PCR-DGGE                Survival curves     NS
  Silini             1994       ADC             I--IV       109           PCR-DGGE                Survival curves     NS
  Slebos             1990       ADC             I--IIIA     69            PCR-ASO                 Log rank            Negative
  Sugio              1992       ADC             I--IV       115           PCR-dot blot            Survival curves     NS
  Tomizawa           2002       ADC             I           110           PCR-seq                 Log rank            NS
  Visscher           1997       ADC             I--IV       31            PCR-SSCP                No data             NS
  Volm (KRAS2)       1993       NSCLC           I--III      206           IHC                     No data             NS
  Wang               1998       ALL             I--IV       53            PCR-seq                 HR                  NS
  Westra             1993       ADC             I--III      57            PCR-ASO                 No data             NS

*N* pts=number of patients; HR=hazard ratio; NSCLC=non-small-cell lung cancer; ADC=adenocarcinoma; SCLC=small-cell lung carcinoma; LC=large cell; NC=nonconclusive; NS=nonsignificative; PCR=polymerase chain reaction; SSCP=single-strand conformation polymorphism; RFLP=restriction fragment length polymorphism; ASO=allele-specific oligonucleotide hybridisation; DGGE=denaturating gradient gel electrophoresis; seq=PCR followed by sequencing of olignucleotide; EPCR=mutant-enriched PCR; IHC=immunohistochemistry; HR estimation=description of the methods used to estimate the individual HR according the three corresponding of the three different methods described in the statistics paragraph.

###### 

Results of the methodological assessment of (a) eligible studies by the European Lung Cancer Working Party score and (b) evaluable studies by the European Lung Cancer Working Party score

                                **Global score (%)**   **Design (%)**   **Laboratory methodology (%)**   **Generalisability (%)**   **Results analysis (%)**
  ----------------------------- ---------------------- ---------------- -------------------------------- -------------------------- --------------------------
  \(a\)                                                                                                                              
  All studies (*N*=43)          52.2                   40               50                               67                         50
  *Date of publication*                                                                                                              
   *r* Spearman                 0.28                   0.18             0.26                             0.42                       0.07
   *P*-value                    0.07                   0.23             0.09                             **0.004**                  0.65
                                                                                                                                     
  *Patient number*                                                                                                                   
   *r* Spearman                 0.50                   0.47             0.14                             0.19                       0.47
   *P*-value                    **0.0006**             **0.001**        0.36                             0.22                       **0.002**
                                                                                                                                     
  Significant (*n*=10)          51.50                  40               46                               62.5                       62.5
  Nonsignificant (*n*=31)       53.83                  40               50                               66.7                       50
   *P-*value                    0.9                    0.93             0.35                             0.39                       0.41
                                                                                                                                     
  Evaluable (*n*=29)            55.23                  40               50                               66.7                       62.5
  Nonevaluable (*n*=14)         44.31                  45               46                               62.5                       31.3
   *P*-value                    0.10                   0.67             0.66                             0.8                        **0.001**
                                                                                                                                     
  *Method of revelation*                                                                                                             
   IHC (*n*=9)                  58.51                  50               64.3                             66.7                       62.5
   Molecular biology (*n*=34)   49.93                  40               46                               62.5                       50
   *P*-value                    **0.029**              0.53             **0.002**                        0.1                        0.22
                                                                                                                                     
  *PCR subgroups*                                                                                                                    
   SSCP (*n*=10)                48.69                  45               42                               66.7                       50
   RFLP (*n*=8)                 52.56                  50               46                               62.5                       75
   *P*-value                    0.33                   0.39             0.71                             0.86                       0.16
                                                                                                                                     
  *Calculation of HR*                                                                                                                
   HR (*n*=6)                   62.35                  50               50                               71                         75
   Log rank (*n*=10)            52.96                  40               46.4                             70.8                       62.5
   Survival curve (*n*=13)      45.92                  40               50                               66.7                       50
   No data (*n*=14)             44.31                  45               46                               62.5                       31.3
   *P*-value                    0.10                   0.62             0.62                             0.52                       **0.001**
                                                                                                                                     
  \(b\)                                                                                                                              
  Evaluable studies (*n*=29)    55.24                  40               50                               66.7                       62.5
  *Date of publication*                                                                                                              
   *r* Spearman                 0.36                   0.27             0.25                             0.44                       0.12
   *P*-value                    0.05                   0.17             0.19                             **0.02**                   0.54
                                                                                                                                     
  *Number of patient*                                                                                                                
   *r* spearman                 0.52                   0.69             0.05                             0.34                       0.34
   *P*-value                    **0.004**              **0.00003**      0.80                             0.07                       **0.07**
                                                                                                                                     
  Significant (*n*=8)           53.33                  40               46                               62.5                       62.5
  Nonsignificant (*n*=21)       55.42                  40               50                               66.7                       62.5
   *P-*value                    0.92                   0.82             0.41                             0.44                       0.65
                                                                                                                                     
  *Method of revelation*                                                                                                             
   IHC (*n*=7)                  57.59                  50               57                               66.7                       62.5
   Molecular biology (*n*=22)   51.46                  40               50                               62.5                       62.5
   *P*-value                    0.24                   0.52             **0.04**                         0.19                       0.69
                                                                                                                                     
  *PCR subgroups*                                                                                                                    
   SSCP (*n*=3)                 53.83                  40               42                               75                         50
   RFLP (*n*=7)                 52.08                  50               42                               58.3                       75
   *P*-value                    0.73                   0.42             0.82                             0.73                       0.36
                                                                                                                                     
  *Calculation of HR*                                                                                                                
   HR (*n*=6)                   62.35                  50               50                               70.8                       75
   Log rank (*n*=10)            52.96                  40               46.4                             70.8                       62.5
   Survival curves (*n*=13)     45.92                  40               50                               66.7                       50
   *P*-value                    0.18                   0.47             0.43                             0.30                       **0.037**

*r* Spearman=correlation coefficient of Spearman; IHC=immunohistochemistry; PCR=polymerase chain reaction; SSCP=single-strand conformation polymorphism; RFLP=restriction fragment length polymorphism; HR=hazard ratio. The *P*-values are in bold when the statistical test is significant.

###### 

Hazard ratio (HR) value for the NSCLC subgroup according to histology, stage and laboratory technique

                                      **Nb**   **Patients**   **Fixed effects HR (95% CI)**    ***χ*^2^ Heterogeneity test**  **Random effects HR (95% CI)**
  ------------------- --------------- -------- -------------- ------------------------------- ------------------------------- --------------------------------
  Overall                             28       3620           1.30 (1.20--1.49)                          *P*=0.01             **1.35 (1.16--1.56)**
  Histology           Squamous        4        280            1.49 (0.88--2.52)                          *P*=0.48              
                      ADC             15       1436           1.52 (1.30--1.78)                          *P*=0.02             **1.59 (1.26--2.02)**
  Disease stage       Stages I        5        562            1.26 (0.94--1.69)                          *P*=0.43              
                      Stages I--III   7        882            1.20 (0.93--1.53)                          *P*=0.42              
                      Stages I--IV    11       1553           1.25 (1.04--1.50)                          P\<0.001             1.41 (0.99--1.99)
  Laboratory method   IHC             7        989            1.08 (0.86--1.34)                          *P*=0.21              
                      PCR             23       2631           1.39 (1.22--1.58)                          *P*=0.03             **1.40 (1.18--1.65)**
  PCR subgroups       RFLP            6        765            **1.70 (1.31--2.19)**                      *P*=0.53              
                      SSCP            3        361            1.32 (0.72--1.47)                          *P*=0.06              
  ADC                 IHC             4        266            1.57 (1.13--2.16)                          *P*=0.01             1.48 (0.76--2.87)
                      PCR             11       1170           **1.50 (1.26--1.80)**                       *P*=0.1              

Nb=number of studies; ADC=adenocarcinomas; IHC=immunohistochemistry; PCR=polymerase chain reaction; SSCP=single-strand conformation polymorphism; RFLP=restriction fragment length polymorphism; statistically significant results are in bold.
